在严重的脱毛率方面,JAK抑制剂的短期恶性瘤风险:一个多中心队列研究
Jasmine Levine1, Rahib K Islam2, Lillian Mo1
1Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA.
Archives of dermatological research
|May 14, 2025
概括
雅努斯酶抑制剂 (JAKis) 没有显示白区 (AA) 患者恶性瘤风险增加. 然而,在这项研究中,传统的免疫抑制剂与更高的内部和血液恶性瘤风险有关.
科学领域:
- 皮肤病学和免疫学
- 药理学和瘤学 药理学和瘤学
背景情况:
- 脱发症 (AA) 是一种自身免疫性疾病.
- 简氏激酶抑制剂 (JAKis) 是有效的AA治疗方法.
- 有关JAKi相关的恶性瘤风险存在担忧,主要来自类风湿性关节炎研究.
研究的目的:
- 为了评估JAKis与严重脱发区患者恶性瘤风险之间的关联.
- 为了在AA中比较JAKis,传统免疫抑制剂和没有全身治疗之间的恶性瘤风险.
主要方法:
- 使用 TriNetX 全球协作网络进行的回顾性队列研究.
- 倾向得分与考克斯的比例危险模型相匹配.
- 状细胞癌 (SCC) /基底细胞癌 (BCC),内部和血液恶性瘤的分析.
主要成果:
- 在JAKi和传统免疫抑制剂使用者之间,SCC/BCC风险没有显著差异.
- 与JAKis相比,传统的免疫抑制剂具有显著更高的内部和血液恶性瘤风险.
- 在接受JAKi治疗和未接受治疗的患者之间,整体恶性瘤风险没有显著差异.
结论:
- 在这项研究中,JAKis并没有在白发病患者中显示出恶性瘤风险的增加.
- 传统的免疫抑制剂与某些恶性瘤的风险增加有关.
- 需要进一步的长期研究,以充分阐明AA中的JAKi安全性.
相关概念视频
The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K
Skin Cancer
3.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


